Back to Report Store Home

Heart Failure Therapeutics in Asia-Pacific Markets to 2024 - Growth Driven by Rising Geriatric Population and Increasing Uptake of Recently Launched Therapy

  • Published: Sep-2018
  • Report Code: GBIHC482MR
  • Report Format: pdf

Description

Table of Contents

1 Table of Contents 5

1.1 List of Tables 7

1.2 List of Figures 8

2 Introduction 10

2.1 Disease Introduction 10

2.2 Epidemiology 10

2.3 Symptoms 11

2.4 Etiology and Pathophysiology 12

2.4.1 Pathophysiology 15

2.5 Diagnosis 16

2.5.1 Diagnostic Algorithm for Chronic HF 16

2.5.2 Diagnostic Algorithm for Acute HF 19

2.6 Disease Classification 20

2.6.1 Co-morbidities and Complications 22

2.7 Prognosis 23

2.8 Treatment Options and Treatment Algorithm 24

2.8.1 Treatment Options 24

2.8.2 Treatment Algorithm 26

2.8.3 Non-pharmacological Treatments 31

3 Marketed Products 32

3.1 Overview 32

3.1.1 Entresto (sacubitril plus valsartan) – Novartis 33

3.1.2 Procoralan (ivabradine) – Les Laboratoires Servier 35

3.1.3 Angiotensin-Converting Enzyme Inhibitors 36

3.1.4 Angiotensin Receptor Blockers 37

3.1.5 Diuretics 38

3.1.6 Beta Blockers 39

3.1.7 Mineralocorticoid Receptor Antagonists 40

3.1.8 Digoxin 41

3.2 Comparative Efficacy and Safety of Marketed Products 42

4 Pipeline Analysis 44

4.1 Pipeline by Stage of Development, Molecule Type, Route of Administration and Program Type 44

4.2 Pipeline by Molecular Target 47

4.3 Promising Pipeline Candidates 49

4.3.1 Omecamtiv mecarbil (CK-1827452/AMG-423) – Cynokinetics 49

4.3.2 Vericiguat – Bayer/Merck & Co. 50

4.4 Comparative Efficacy and Safety of Pipeline Products 52

4.5 Product Competitiveness Framework 53

5 Clinical Trial Analysis 54

5.1 Failure Rate 54

5.1.1 Overall Failure Rate 54

5.1.2 Failure Rate by Phase and Molecule Type 56

5.1.3 Failure Rate by Phase and Molecular Target 57

5.2 Clinical Trial Size 58

5.2.1 Patient Enrollment per Product by Molecule Type and Stage of Development 58

5.2.2 Patient Enrollment per Product by Molecular Target and Stage of Development 59

5.2.3 Patient Enrollment per Trial by Molecule Type and Stage of Development 60

5.2.4 Patient Enrollment per Trial by Molecular Target and Stage of Development 61

5.3 Clinical Trial Duration 62

5.3.1 Trial Duration by Molecule Type and Stage of Development 62

5.3.2 Trial Duration by Molecular Target and Stage of Development 63

5.4 Summary of Clinical Trial Metrics 64

6 Multi-scenario Forecast 65

6.1 Geographical Markets 65

6.2 Asia-Pacific Market 65

6.3 India 67

6.3.1 Treatment Usage Patterns 67

6.3.2 Annual Cost of Therapy 68

6.3.3 Market Size 69

6.4 China 70

6.4.1 Treatment Usage Patterns 70

6.4.2 Annual Cost of Therapy 71

6.4.3 Market Size 73

6.5 Australia 74

6.5.1 Treatment Usage Patterns 74

6.5.2 Annual Cost of Therapy 75

6.5.3 Market Size 76

6.6 South Korea 77

6.6.1 Treatment Usage Patterns 77

6.6.2 Annual Cost of Therapy 78

6.6.3 Market Size 79

6.7 Japan 80

6.7.1 Treatment Usage Patterns 80

6.7.2 Annual Cost of Therapy 81

6.7.3 Market Size 82

7 Drivers and Barriers 84

7.1 Drivers 84

7.1.1 Rising Prevalence and Growing Awareness of the Disease to Drive Market Growth 84

7.1.2 Promising Pipeline Products that Target Unmet Needs for HF 84

7.1.3 Increasing Awareness and Diversified Healthcare Reform to Boost Market Growth 84

7.1.4 Launch of Entresto and its Label Expansion will Drive Market Growth 85

7.2 Barriers 85

7.2.1 Market Access for New Therapies as well as Crowded and Cheap Generic Market 85

7.2.2 Lack of Development of Acute HF Pipeline Products 85

7.2.3 Reluctance of Cardiologists to Adopt New Therapies 86

8 Deals and Strategic Consolidations 87

8.1 Licensing Deals 87

8.1.1 Deals by Region and Value 87

8.1.2 Number of Disclosed and Undisclosed Deals by Year, Aggregate Deal Value 89

8.1.3 Deal Value by Stage of Development, Molecule Type, and Molecular Target 90

8.1.4 Key Licensing Deals 92

8.2 Co-development Deals 95

8.2.1 Deals by Region and Value 95

8.2.2 Number of Disclosed and Undisclosed Deals by Year, Aggregate Deal Value 96

8.2.3 Deal Value by Stage of Development, Molecule Type, and Molecular Target 97

8.2.4 Key Co-development Deals 99

9 Appendix 101

9.1 All Pipeline Drugs by Stage of Development 101

9.1.1 Discovery 101

9.1.2 Preclinical 102

9.1.3 IND/CTA-filed 105

9.1.4 Phase I 105

9.1.5 Phase II 106

9.1.6 Phase III 107

9.1.7 Pre-registration 107

9.2 Summary of Multi-scenario Market Forecasts to 2024 107

9.2.1 Asia-Pacific 107

9.2.2 India 108

9.2.3 China 108

9.2.4 Australia 109

9.2.5 South Korea 109

9.2.6 Japan 110

9.3 Bibliography 110

9.4 Abbreviations 115

9.5 Research Methodology 117

9.5.1 Secondary Research 118

9.5.2 Marketed Product Profiles 118

9.5.3 Late-Stage Pipeline Candidates 118

9.5.4 Comparative Efficacy and Safety Heat Map for Marketed and Pipeline Products 118

9.5.5 Product Competitiveness Framework 119

9.5.6 Pipeline Analysis 119

9.5.7 Forecasting Model 119

9.5.8 Deals Data Analysis 120

9.6 Contact Us 121

9.7 Disclaimer 121

 
      captcha refresh

I have read and accept terms and conditions and privacy policy

Cancel
License Details
Electronic PDF copy delivered via email. Report can be used by individual purchaser only.
Single User Licence
$4995
Electronic PDF copy delivered via email. Report can be shared by unlimited users within one corporate location, e.g. a regional office.
Site Licence
$9990
Electronic PDF copy delivered via email. Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company.
Global Licence
$14985
Email to a colleague Request Sample Pages Enquire Before Buying
Prefer to speak to a team member? Call us on:
+44 161 359 5414
Or click here to contact us
Secure Payments
Cards